OVID is the heart of a national and international academic network with decades of experience in clinical psychopharmacology and clinical trials. This network is strongly connected to preclinical researchers and clinical facilities. OVID develops new psychedelics, evaluates established substances in clinical studies, and makes them available to patients.
As part of an academic network, we are at the forefront of psychedelic research in Germany. We are working to improve the availability of psychedelics for clinical and scientific use in Germany.
We are working on the infrastructure for the clinical implementation of psilocybin-assisted treatment for depression and we are planning further clinical studies in various psychiatric disorders.
We are working on the development of new psychedelic substances with properties that make them more suitable for routine clinical use.
Sign up for our newsletter and we’ll keep you up to date on our latest developments!